PriceTargets.com logo

Angion Biomedica - ANGN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 06/1/2023 05:00 PM ET
+0 (0.00%)
Get New Angion Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANGN

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Angion Biomedica in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ANGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Angion Biomedica. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/18/2022HC WainwrightDowngradeBuy ➝ NeutralLow
6/30/2022Stifel NicolausDowngradeBuy ➝ HoldLow
6/30/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
5/23/2022HC WainwrightLower TargetBuy$320.00 ➝ $280.00Medium
4/18/2022HC WainwrightLower TargetBuy$500.00 ➝ $320.00Medium
12/10/2021OppenheimerLower TargetOutperform ➝ Outperform$150.00 ➝ $80.00High
11/15/2021HC WainwrightReiterated RatingBuy$490.00High
11/9/2021HC WainwrightLower TargetBuy$1,000.00 ➝ $500.00Low
10/27/2021Stifel NicolausLower TargetBuy$400.00 ➝ $150.00High
10/27/2021OppenheimerLower TargetOutperform$380.00 ➝ $150.00High
9/13/2021HC WainwrightReiterated RatingBuy$1,000.00Medium
8/31/2021HC WainwrightReiterated RatingBuy$1,000.00Low
8/3/2021HC WainwrightReiterated RatingBuy$1,000.00High
6/30/2021HC WainwrightReiterated RatingBuy$1,000.00High
3/31/2021OppenheimerReiterated RatingBuy$380.00Low
3/2/2021OppenheimerInitiated CoverageOutperform$380.00High
3/2/2021Stifel NicolausInitiated CoverageBuy$400.00High
3/2/2021CowenInitiated CoverageOutperformHigh
3/1/2021HC WainwrightInitiated CoverageBuy$1,000.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Angion Biomedica logo
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $6.48
Low: $1.00
High: $10.00

52 Week Range

Now: N/A

Volume

224,800 shs

Average Volume

86,718 shs

Market Capitalization

$30.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Angion Biomedica?

The following Wall Street research analysts have issued research reports on Angion Biomedica in the last twelve months:
View the latest analyst ratings for ANGN.

What is the current price target for Angion Biomedica?

0 Wall Street analysts have set twelve-month price targets for Angion Biomedica in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Angion Biomedica in the next year.
View the latest price targets for ANGN.

What is the current consensus analyst rating for Angion Biomedica?

Angion Biomedica currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ANGN.

What other companies compete with Angion Biomedica?

Other companies that are similar to Angion Biomedica include Orphazyme A/S, Tevogen Bio, LianBio, Enlivex Therapeutics and Celyad Oncology. Learn More about companies similar to Angion Biomedica.

How do I contact Angion Biomedica's investor relations team?

Angion Biomedica's physical mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The company's listed phone number is 415-655-4899 and its investor relations email address is [email protected]. The official website for Angion Biomedica is www.angion.com. Learn More about contacing Angion Biomedica investor relations.